What's the Media Buzz Surrounding Novavax (NVAX)?

By Blake Campbell • Monday, January 09 16:21 • Permanent Link

Novavax rose 11.3% during the aftermarket session to $12.26 per share. As reported by Reuters: "Jan 9 ( Reuters ) - Novavax Inc ( NVAX.O ) said on Monday its longtime chief executive officer, Stanley Erck, would retire and be succeeded by industry veteran John Jacobs, at a time when the COVID-19 vaccine maker looks to catch up with larger rivals. Novavax shares were up about 5% in ..." You can read more about it here. For those of you thinking about investing in the stock, here is a brief look at the company's fundamentals.

Here's an overview of Novavax's recent cash flows and operating margins:

Date Reported	Cash Flow from Operations ($ MM)	Capital expenditures ($ MM)	Free Cash Flow ($ MM)	YoY Growth (%)
2021-12-31	323	-57	265	373.21
2020-12-31	-43	-55	-97	29.84
2019-12-31	-137	-2	-138	n/a

None

Date Reported	Total Revenue ($ MM)	Operating Expenses ($ MM)	Operating Margins (%)	YoY Growth (%)
2021-12-31	1,146	2,833	-147.13	-67.92
2020-12-31	476	892	-87.62	87.38
2019-12-31	19	148	-694.44	n/a

At today's price of $12.26 per share, Novavax is -77.84% away from its target price of $55.33, and on average, analysts give the stock a rating of hold. 31.3% of the company's shares are linked to short positions, and 43.6% of the shares are owned by institutional investors.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.